Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction FLOT Followed by Neoadjuvant Chemoradiation in Resectable Esophageal/GEJ Adenocarcinoma
NCT04028167Phase 2Active, not recruiting
- Sponsor
- University of Colorado Denver
- Start
- Apr 2020
- Primary completion
- Jan 2026
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of docetaxel, oxaliplatin, fluorouracil, folinic acid in esophageal adenocarcinoma (EAC), gastroesophageal junction adenocarcinoma, sponsored by University of Colorado Denver. Started Apr 2020; status: active, not recruiting.
02
Drugs
docetaxeloxaliplatinfluorouracilfolinic acid
03
Conditions
esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04028167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04028167.